Inify Laboratories - notice of Extraordinary General Meeting on December 4, 2025

Stockholm – November 12, 2025 - Inify Laboratories AB (publ), a unique laboratory service that provides cancer diagnostics within pathology, hereby invites its shareholders to Extraordinary General Meeting on December 4, 2025.

Please find attached the invitation including attachment, agenda and details on how to register and vote. The invitation is also available on the company's website: www.inify.com.

For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: [email protected] or: [email protected].

###

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis.  The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis - using a fully digital, standardised and AI-assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Stockholm, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo under the ticker INIFY.

###

This information is subject to the disclosure requirements pursuant to section 5–12 of the Norwegian Securities Trading Act.